• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

    118.16 -2.07 (-1.72%)
    Streaming Delayed Price Updated: 2:01 PM EDT, Aug 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 173,677
    Open 119.40
    Bid (Size) 118.09 (100)
    Ask (Size) 118.39 (100)
    Prev. Close 120.23
    Today's Range 117.63 - 121.97
    52wk Range 39.84 - 130.05
    Shares Outstanding 55,307,775
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript ↗
    Enrollment completed six months early; $1.5B cash runway into 2029. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Kymera Therapeutics Q2 Earnings Call Highlights ↗
    Kymera Therapeutics (NASDAQ:KYMR) said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by... 
    Via MarketBeat
    Topics Earnings

    Performance

    YTD
    +62.4%
    +62.4%
    1 Month
    +11.3%
    +11.3%
    3 Month
    +45.1%
    +45.1%
    6 Month
    +24.3%
    +24.3%
    1 Year
    +179.6%
    +179.6%

    More News

    Read More
    News headline image
    Kymera's CEO Sold $6 Million in Stock After a 170% Run ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Kymera Therapeutics (NASDAQ:KYMR) Soars on Q1 2026 Revenue and EPS Beat ↗
    Via Chartmill
    Kymera Therapeutics Inc (NASDAQ:KYMR) Stock Falls 6.6% After Q4 2025 Earnings Miss and Extended Clinical Timelines ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Why Kymera Therapeutics Stock Popped This Week ↗
    Via The Motley Fool
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data ↗
    Via MarketBeat
    News headline image
    Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗
    Via The Motley Fool
    News headline image
    What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
    Via The Motley Fool
    Topics Initial Public Offering
    News headline image
    Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Kymera (KYMR) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗
    Via The Motley Fool
    News headline image
    Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is Kymera Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Kymera Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Kymera Therapeutics, Inc. - Common Stock trade on?
    Kymera Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Kymera Therapeutics, Inc. - Common Stock?
    The ticker symbol for Kymera Therapeutics, Inc. - Common Stock is KYMR on the Nasdaq Stock Market
    What is the current price of Kymera Therapeutics, Inc. - Common Stock?
    The current price of Kymera Therapeutics, Inc. - Common Stock is 118.16
    When was Kymera Therapeutics, Inc. - Common Stock last traded?
    The last trade of Kymera Therapeutics, Inc. - Common Stock was at 08/28/26 02:01 PM ET
    What is the market capitalization of Kymera Therapeutics, Inc. - Common Stock?
    The market capitalization of Kymera Therapeutics, Inc. - Common Stock is 6.54B
    How many shares of Kymera Therapeutics, Inc. - Common Stock are outstanding?
    Kymera Therapeutics, Inc. - Common Stock has 7B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.